Body mass index in type 2 spinal muscular atrophy: a longitudinal study

被引:0
作者
Gloria Ferrantini
Giorgia Coratti
Roberta Onesimo
Simona Lucibello
Sarah Bompard
Ida Turrini
Graziamaria Cicala
Michela Caprarelli
Maria Carmela Pera
Chiara Bravetti
Beatrice Berti
Valentina Giorgio
Claudio Bruno
Noemi Brolatti
Chiara Panicucci
Adele D’Amico
Antonella Longo
Chiara Leoni
Valeria A. Sansone
Emilio Albamonte
Sonia Messina
Maria Sframeli
Enrico Bertini
Marika Pane
Eugenio Mercuri
机构
[1] Università Cattolica del Sacro Cuore,Pediatric Neurology
[2] Centro Clinico Nemo,Center of Experimental and Translational Myology
[3] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences
[4] Pediatric Unit,Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud
[5] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[6] IRCCS Istituto Giannina Gaslini,undefined
[7] IRCCS Bambino Gesù Children’s Hospital,undefined
[8] Neurorehabilitation Unit,undefined
[9] University of Milan,undefined
[10] Neuromuscular Omnicentre Clinical Center,undefined
[11] Niguarda Hospital,undefined
[12] University of Messina,undefined
来源
European Journal of Pediatrics | 2022年 / 181卷
关键词
Neonate; Children; Spinal muscular atrophy; Body mass index; Nutritional status;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this retrospective study was to review body mass index (BMI) in a large cohort of Italian pediatric type 2 spinal muscular atrophy (SMA) patients, aged between 0 and 20 years and to establish possible differences in relation to a number of variables such as ventilation, motor function, and survival motor neuron 2 gene copies. Cross-sectional data were collected from 102 patients for a total of 344 visits. Standard growth charts for height and weight were used as reference, with age adjusted BMI calculated using the Center for Disease and Prevention Children’s BMI Tool. In the 344 visits, weight ranged between 3.90 and 83 kg, and the BMI between 8.4 and 31.6 with a BMI/age z-scores <  − 2SD present in 28% and BMI/age z-scores >  + 2SD in 9% of the measurements. The BMI/age z-scores were relatively stable < 5 years of age with an increasing number of patients <  − 2SD after the age of 5, and a wider range of BMI/age z-scores after the age of 13. A difference on the BMI/age z-scores was found among the different age subgroups (< 5, 5–12, ≥ 13 years). A multivariate analysis in 58 patients with longitudinal assessments showed that baseline BMI/age z-scores and gender were significantly contributing to the changes while other variables were not.
引用
收藏
页码:1923 / 1932
页数:9
相关论文
共 448 条
[1]  
D'Amico A(2011)Spinal muscular atrophy Orphanet J Rare Dis 6 71-1732
[2]  
Mercuri E(2017)Nusinersen versus sham control in infantile-onset spinal muscular atrophy N Engl J Med 377 1723-635
[3]  
Tiziano FD(2018)Nusinersen versus sham control in later-onset spinal muscular atrophy N Engl J Med 378 625-923
[4]  
Bertini E(2021)Risdiplam in type 1 spinal muscular atrophy N Engl J Med 384 915-1722
[5]  
Mendell JR(2017)Single-dose gene-replacement therapy for spinal muscular atrophy N Engl J Med 377 1713-325
[6]  
Al-Zaidy S(2020)Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study Lancet Neurol 19 317-127
[7]  
Shell R(2018)Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1 Eur J Paediatr Neurol 22 122-e1318
[8]  
Arnold WD(2018)Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study Neurology 91 e1312-42
[9]  
Rodino-Klapac LR(2020)Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients Eur J Paediatr Neurol 27 37-771
[10]  
Prior TW(2020)Gain and loss of abilities in type II SMA: a 12-month natural history study Neuromuscul Disord 30 765-1117